Author

Tokuko Toyota

Institution: Juntendo University

Observed institution: Juntendo University

OpenAlex ID: A5033479356

Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma

2021 · Sakiko Harada, Miki Ando, et al. · Molecular Therapy · 43

Sustainable Tumor-Suppressive Effect of iPSC-Derived Rejuvenated T Cells Targeting Cervical Cancers

2020 · Tadahiro Honda, Miki Ando, et al. · Molecular Therapy · 31

iPSC-derived hypoimmunogenic tissue resident memory T cells mediate robust anti-tumor activity against cervical cancer

2023 · Yoshiki Furukawa, Midori Ishii, et al. · Cell Reports Medicine · 24

iPSC-Derived Neoantigen-Specific CTL Therapy for Ewing Sarcoma

2021 · Midori Ishii, Jun Ando, et al. · Cancer Immunology Research · 19

Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper/cytotoxic CD4 T cells in chronic myelogenous leukemia patients

2018 · Naoki Watanabe, Tomoiku Takaku, et al. · International Journal of Hematology · 14

Establishment of ganglioside GD2-expressing extranodal NK/T-cell lymphoma cell line with scRNA-seq analysis

2023 · Shoko Sato, Midori Ishii, et al. · Experimental Hematology · 4

Generation of iPSC-derived CD4 + Th1 cells enhancing chimeric antigen receptor-T cell cytotoxicity

2025 · Yoshiki Furukawa, Midori Ishii, et al. · bioRxiv (Cold Spring Harbor Laboratory)

Data from iPSC-Derived Neoantigen-Specific CTL Therapy for Ewing Sarcoma

2023 · Midori Ishii, Jun Ando, et al.

Supplementary Figure and Table from iPSC-Derived Neoantigen-Specific CTL Therapy for Ewing Sarcoma

2023 · Midori Ishii, Jun Ando, et al.

Data from iPSC-Derived Neoantigen-Specific CTL Therapy for Ewing Sarcoma

2023 · Midori Ishii, Jun Ando, et al.

Supplementary Figure and Table from iPSC-Derived Neoantigen-Specific CTL Therapy for Ewing Sarcoma

2023 · Midori Ishii, Jun Ando, et al.

Works count: 11

Citation count: 135

H-index: 5

I10-index: 5